OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Portland, Oregon, United States1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hepatomegaly, Hypertrophy, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Splenomegaly, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, liver disorder | Active, not recruiting | Phase 2 | 2026-09-01 | NCT03801434 |